[go: up one dir, main page]

CN101222911A - 新的制粒方法及由此制备的颗粒 - Google Patents

新的制粒方法及由此制备的颗粒 Download PDF

Info

Publication number
CN101222911A
CN101222911A CNA2005800510501A CN200580051050A CN101222911A CN 101222911 A CN101222911 A CN 101222911A CN A2005800510501 A CNA2005800510501 A CN A2005800510501A CN 200580051050 A CN200580051050 A CN 200580051050A CN 101222911 A CN101222911 A CN 101222911A
Authority
CN
China
Prior art keywords
pharmaceutically acceptable
granule
sugar
active pharmaceutical
pharmaceutical ingredient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2005800510501A
Other languages
English (en)
Chinese (zh)
Inventor
I·扎利特
J·赫拉科夫斯基
R·特嫩高泽
S·沙洛姆-克莱因
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Teva Pharmaceutical Industries Ltd
Original Assignee
Teva Pharmaceutical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharmaceutical Industries Ltd filed Critical Teva Pharmaceutical Industries Ltd
Publication of CN101222911A publication Critical patent/CN101222911A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CNA2005800510501A 2005-07-15 2005-07-15 新的制粒方法及由此制备的颗粒 Pending CN101222911A (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2005/025326 WO2007011349A1 (fr) 2005-07-15 2005-07-15 Nouveau procede de granulation et granule produit par ce procede

Publications (1)

Publication Number Publication Date
CN101222911A true CN101222911A (zh) 2008-07-16

Family

ID=35045306

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2005800510501A Pending CN101222911A (zh) 2005-07-15 2005-07-15 新的制粒方法及由此制备的颗粒

Country Status (6)

Country Link
EP (1) EP1793801A1 (fr)
JP (1) JP2008540644A (fr)
CN (1) CN101222911A (fr)
CA (1) CA2614468A1 (fr)
IL (1) IL188177A0 (fr)
WO (1) WO2007011349A1 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102238941A (zh) * 2008-09-17 2011-11-09 迈兰实验室公司 颗粒、制备它们的方法和包含它们的药物产品
CN108524527A (zh) * 2017-03-02 2018-09-14 北京德立福瑞医药科技有限公司 塞来昔布药物组合物及其制备方法
CN114177157A (zh) * 2015-06-30 2022-03-15 基因泰克公司 含有药物的立即释放片剂和用于形成片剂的方法

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2036545A1 (fr) 2006-01-05 2009-03-18 Teva Pharmaceutical Industries Ltd. Comprimés d'aripiprazole
US7756534B2 (en) 2006-05-19 2010-07-13 Alcatel-Lucent Usa Inc. Provision of location-based services utilizing user movement statistics
WO2007141806A1 (fr) * 2006-06-02 2007-12-13 Jubilant Organosys Ltd Formulations pharmaceutiques comprenant de l'oxcarbazépine et procédés correspondants
US20080045600A1 (en) * 2006-08-17 2008-02-21 Gawande Rahul S Bicalutamide compositions
GB0702826D0 (en) * 2007-02-14 2007-03-28 Pliva Istrazivanje I Razvoj D Preparation and composition of solid dosage form containing Bicalutamide
JP5389341B2 (ja) * 2007-07-24 2014-01-15 小林化工株式会社 保存安定性に優れたビカルタミド含有製剤の製造方法
JP5204452B2 (ja) * 2007-10-02 2013-06-05 日医工株式会社 ビカルタミド含有製剤
PT2165702E (pt) 2008-09-17 2012-02-07 Helm Ag Composições estáveis e rapidamente dissolvidas de candesartan cilexetil preparadas com granulação húmida
US20120010216A1 (en) * 2010-07-06 2012-01-12 Brown Arthur M Pharmaceutical compositions containing vanoxerine
EP3958841A1 (fr) * 2019-04-22 2022-03-02 Mylan Specialty L.P. Compositions de co-cristaux de méloxicam
US20220047506A1 (en) 2020-08-12 2022-02-17 Villya LLC Praziquantel Formulations
CN111759820B (zh) * 2020-08-24 2022-04-19 武汉人福药业有限责任公司 一种奥卡西平片剂及其制备方法
WO2024158694A1 (fr) 2023-01-23 2024-08-02 Villya LLC Compositions et méthodes pour améliorer la solubilité d'agents thérapeutiques du dysfonctionnement érectile

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2758459B1 (fr) * 1997-01-17 1999-05-07 Pharma Pass Composition pharmaceutique de fenofibrate presentant une biodisponibilite elevee et son procede de preparation
EP0945134A1 (fr) * 1998-03-27 1999-09-29 Boehringer Ingelheim Pharma KG Nouvelles formes galeniques du meloxicam pour administration par voie orale
US20020071857A1 (en) * 2000-08-18 2002-06-13 Kararli Tugrul T. Rapidly disintegrating oral formulation of a cyclooxygenase-2 inhibitor
AR033485A1 (es) * 2001-09-25 2003-12-26 Otsuka Pharma Co Ltd Sustancia medicinal de aripiprazol de baja higroscopicidad y proceso para la preparacion de la misma
DE10250081A1 (de) * 2002-10-25 2004-05-13 Boehringer Ingelheim Vetmedica Gmbh Wasserlösliche Meloxicam Granulate
US20050008691A1 (en) * 2003-05-14 2005-01-13 Arturo Siles Ortega Bicalutamide compositions

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102238941A (zh) * 2008-09-17 2011-11-09 迈兰实验室公司 颗粒、制备它们的方法和包含它们的药物产品
CN114177157A (zh) * 2015-06-30 2022-03-15 基因泰克公司 含有药物的立即释放片剂和用于形成片剂的方法
CN108524527A (zh) * 2017-03-02 2018-09-14 北京德立福瑞医药科技有限公司 塞来昔布药物组合物及其制备方法
CN108524527B (zh) * 2017-03-02 2020-08-04 北京德立福瑞医药科技有限公司 塞来昔布药物组合物及其制备方法

Also Published As

Publication number Publication date
CA2614468A1 (fr) 2007-01-25
JP2008540644A (ja) 2008-11-20
WO2007011349A1 (fr) 2007-01-25
IL188177A0 (en) 2008-03-20
EP1793801A1 (fr) 2007-06-13

Similar Documents

Publication Publication Date Title
US7074417B2 (en) Multiple-delayed release anti-viral product, use and formulation thereof
CN101222911A (zh) 新的制粒方法及由此制备的颗粒
JP2011063611A (ja) シロスタゾール製剤
CN104546747A (zh) 一种含有甲磺酸沙芬酰胺的药物组合物及其制备方法
ZA200309289B (en) Oxcarbazepine dosage forms.
CA2621079A1 (fr) Granule broye seche et procedes associes
JP2001163769A (ja) シロスタゾール製剤
US7157095B2 (en) Multiple-delayed release antifungal product, use and formulation thereof
WO2003082241A2 (fr) Formulations de clarithromycine dotees d'une biodisponibilite amelioree
US20070014854A1 (en) Novel granulation process
US20070014864A1 (en) Novel pharmaceutical granulate
KR101060885B1 (ko) 염산 베니디핀 함유 의약 조성물
JPH08310969A (ja) 固形薬品組成物及びその製造方法
US20070014853A1 (en) Pharmaceutical dosage form containing novel pharmaceutical granulate
JP3372242B2 (ja) 徐放性微粒子製剤及びその製造方法
EP0948318B1 (fr) Granules comprenant un compose soluble dans l'eau et de la cellulose
CA2492156C (fr) Composition de comprime contenant un extrait medicinale a base de kampo et procede de production connexe
CN101340896A (zh) 含有低溶解性药物的压缩的固体剂型和其制备方法
JP2009501694A (ja) メシル酸サキナビル経口投与剤型
CA2611737A1 (fr) Formulations contenant du glimepiride et/ou ses sels
JP2864737B2 (ja) 徐放性製剤用基剤並びに徐放性製剤及び該製剤の製造方法
JP4281281B2 (ja) 分岐鎖アミノ酸を含有するドライシロップ剤
KR100981750B1 (ko) 분무-건조 과립 및 그의 제조방법
CN114425039B (zh) 改进的依非韦伦速释制剂
JP2015537013A (ja) 速崩性錠剤

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Open date: 20080716